2.71
前日終値:
$2.81
開ける:
$2.97
24時間の取引高:
621.15K
Relative Volume:
2.17
時価総額:
$75.00M
収益:
-
当期純損益:
$-94.11M
株価収益率:
-0.4509
EPS:
-6.01
ネットキャッシュフロー:
$-86.06M
1週間 パフォーマンス:
-24.51%
1か月 パフォーマンス:
-20.99%
6か月 パフォーマンス:
-65.65%
1年 パフォーマンス:
-70.86%
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
名前
Adverum Biotechnologies Inc
セクター
電話
(650) 649-1004
住所
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ADVM
Adverum Biotechnologies Inc
|
2.71 | 75.00M | 0 | -94.11M | -86.06M | -6.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-06-25 | 開始されました | Oppenheimer | Outperform |
2024-04-30 | 開始されました | H.C. Wainwright | Buy |
2022-07-07 | アップグレード | Truist | Hold → Buy |
2021-07-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2021-05-03 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2021-04-29 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2021-04-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2021-04-29 | ダウングレード | Truist | Buy → Hold |
2020-12-16 | 開始されました | UBS | Neutral |
2020-11-12 | アップグレード | Raymond James | Underperform → Mkt Perform |
2020-06-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2020-05-05 | アップグレード | SunTrust | Hold → Buy |
2020-04-28 | 開始されました | Goldman | Buy |
2020-03-16 | 開始されました | SVB Leerink | Outperform |
2020-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2020-02-10 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2019-10-15 | 繰り返されました | Chardan Capital Markets | Neutral |
2019-09-13 | 繰り返されました | Chardan Capital Markets | Neutral |
2019-06-14 | 再開されました | Raymond James | Mkt Perform |
2018-11-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2018-11-02 | ダウングレード | SunTrust | Buy → Hold |
2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
2018-08-30 | 開始されました | SunTrust | Buy |
2018-02-15 | 再開されました | Piper Jaffray | Overweight |
2017-10-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Adverum Biotechnologies Inc (ADVM) 最新ニュース
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com
Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan
It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News
Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com
Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com
Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com
Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView
Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Chardan Capital Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $33.00 - American Banking and Market News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks
Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Adverum Biotechnologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Adverum Biotechnologies Reports Fourth Quarter and Full - GlobeNewswire
Adverum Advances Gene Therapy Pipeline Despite Wider Losses: Key Q4 Developments Revealed - Stock Titan
Adverum Biotechnologies, Inc. SEC 10-K Report - TradingView
Avalanche Biotechnologies Announces Executive Changes - MarketScreener
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Adverum Biotech Grants 30,000 Share Options to New Executive: Key Details - Stock Titan
Adverum Biotechnologies Inc (ADVM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):